82117-21-3

Usage

Uses

Used in Pharmaceutical Research and Development:
3-Chloro-7-methoxyisoquinoline is used as a lead compound for the development of new drugs, particularly in the areas of antimalarial and antitumor therapies. Its potential therapeutic properties have been studied extensively, and it has shown promise in treating various diseases.
Used in Medicinal Chemistry:
3-Chloro-7-methoxyisoquinoline is used as a building block in the synthesis of various bioactive molecules and pharmaceuticals. Its versatile applications and potential pharmacological benefits make it an important compound in the field of medicinal chemistry.
Used in Antimalarial Applications:
3-Chloro-7-methoxyisoquinoline is used as an antimalarial agent, with studies indicating its potential to treat malaria, a life-threatening disease caused by parasites that are transmitted to people through the bites of infected mosquitoes.
Used in Antitumor Applications:
3-Chloro-7-methoxyisoquinoline is used as an antitumor agent, with research suggesting its potential to combat various types of cancer. Its biological activities and therapeutic properties make it a promising candidate for cancer treatment and drug development.

Upstream product

• 24077-98-3 (Z)-2-(hydroxyimino)-6-methoxy-2,3-dihydro-1H-inden-1-one 
• 24077-98-3 2-(hydroxyimino)-6-methoxy-2,3-dihydro-1H-inden-1-one 
• 24623-40-3 1,3-dichloro-7-methoxyisoquinoline 
• 13623-25-1 6-methoxy-2,3-dihydro-1H-inden-1-one 

Downstream Products

• 1383379-89-2 3-fluoro-4-(7-methoxyisoquinolin-3-yl)benzoic acid 
• 1383379-67-6 3-fluoro-4-(7-hydroxyisoquinolin-3-yl)benzoic acid 
• 82117-25-7 3-chloroisoquinolin-7-ol 

Relevant academic research and scientific papers

BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to bicyclic aryl monobactam compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A1, L, M, W, X, Y, Z, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a bicyclic aryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of one or more beta-lactamase inhibitor compounds.

AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel aminoisoxazoline compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES

Pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts are disclosed, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha- synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, the compounds are used as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. Futher, the compounds are useful for measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.